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Introduction
============

Maintaining a calcium intake of at least 1000-1200 mg/day has long been recommended for older individuals to treat and prevent osteoporosis.[@ref1] [@ref2] Calcium supplements are commonly taken to achieve such intakes, which are considerably higher than the average intake of calcium in the diet in older people in Western countries, around 700-900 mg/day. Recently, concerns have emerged about the risk-benefit profile of calcium supplements. The small reductions in total fractures[@ref3] seem outweighed by the moderate risk of minor side effects such as constipation, coupled with the small risk of severe side effects such as cardiovascular events,[@ref4] [@ref5] [@ref6] kidney stones,[@ref7] and admission to hospital with acute gastrointestinal symptoms.[@ref8] Consequently, some experts have recommended that older people increase their calcium intake through their diet and take supplements only when that is not feasible.[@ref9] In a systematic review of calcium intake and fractures, we concluded that there was no evidence of an association between increased dietary calcium intake and lower risk of fracture.[@ref10] We identified only two small randomised controlled trials of dietary calcium intake that reported fracture as an outcome. Numerous cohort studies, however, assessed the relation between dietary calcium, milk or dairy intake, and risk of fracture, and most reported neutral associations.[@ref10]

The putative mechanism by which calcium intake affects bone health is by increasing bone mineral density (BMD). BMD is a surrogate endpoint for fracture risk that allows biological effects to be explored in randomised controlled trials of modest size. We investigated whether the results of randomised controlled trials with BMD as an endpoint support the recommendations to increase dietary calcium intake to prevent osteoporosis. We undertook a systematic review and meta-analysis of randomised controlled trials of dietary sources of calcium or calcium supplements in older adults (aged \>50) to determine whether increasing intake from dietary sources has effects on BMD and, if so, whether they are similar to the effects of calcium supplements on BMD.

Methods
=======

Literature search
-----------------

As part of a broader search for studies of calcium intake and health, we searched Ovid Medline and Embase in July 2013 and updated the search using Pubmed and Embase in September 2014 for randomised controlled trials of calcium, milk, or dairy intake, or calcium supplements with BMD as an endpoint. We also hand searched recent systematic reviews, meta-analyses, and any other articles included in our review for other relevant articles. Appendix 1 provided details of the searches.

Patient involvement
-------------------

No patients were involved in setting the research question or the outcome measures, nor were they involved in the design and implementation of the study. There are no plans to involve patients in dissemination.

Study selection
---------------

Included studies were randomised controlled trials in participants aged \>50 at baseline with BMD measured by dual energy x ray absorptiometry (DXA) or precursor technology such as photon absorptiometry. We included studies that reported bone mineral content (BMC) because BMD is obtained by dividing BMC by bone area and therefore the two are highly correlated. Studies in which most participants at baseline had a major systemic pathology other than osteoporosis, such as renal failure or malignancy, were excluded. We included studies of calcium supplements used in combination with other treatment provided that the other treatment was given to both arms (such as calcium plus vitamin K versus placebo plus vitamin K), and studies of co-administered calcium and vitamin D supplements (CaD). Randomised controlled trials of hydroxyapatite as a dietary source of calcium were included because it is made from bone and contains other minerals, hormones, protein, and amino acids in addition to calcium. One author (WL or MB) screened titles and abstracts, and two authors (WL, MB, or VT) independently screened the full text of potentially relevant studies. The flow of articles is shown in figure A in appendix 2.

Data extraction and synthesis
-----------------------------

We extracted information from each study on participants' characteristics, study design, funding source and conflicts of interest, and BMD at the lumbar spine, femoral neck, total hip, forearm, and total body. BMD can be measured at several sites in the forearm, although the 33% (1/3) radius is most commonly used. For each study, we used the reported data for the forearm, regardless of site. If more than one site was reported, we used the data for the site closest to the 33% radius. A single author (VT) extracted data, which were checked by a second author (MB). Risk of bias was assessed as recommended in the Cochrane Handbook.[@ref11] Any discrepancies were resolved through discussion.

The primary endpoints were the percentage changes in BMD from baseline at the five BMD sites. We categorised the studies into three groups by duration: one year was duration \<18 months; two years was duration ≥18 months and ≤2.5 years; and others were studies lasting more than two and a half years. For studies that presented absolute data rather than percentage change from baseline, we calculated the mean percentage change from the raw data and the standard deviation of the percentage change using the approach described in the Cochrane Handbook.[@ref11] When data were presented only in figures, we used digital callipers to extract data. In four studies that reported mean data but not measures of spread,[@ref12] [@ref13] [@ref14] [@ref15] we imputed the standard deviation for the percentage change in BMD for each site from the average site and duration specific standard deviations of all other studies included in our review. We prespecified subgroup analyses based on the following variables: dietary calcium intake *v* calcium supplements; risk of bias; calcium monotherapy *v* CaD; baseline age (\<65); sex; community *v* institutionalised participants; baseline dietary calcium intake \<800 mg/day; baseline 25-hydroxyvitamin D \<50 nmol/L; calcium dose (≤500 *v* \>500 mg/day and \<1000 *v* ≥1000 mg/day); and vitamin D dose \<800 IU/day.

Statistics
----------

We pooled the data using random effects meta-analyses and assessed for heterogeneity between studies using the I^2^ statistic (I^2^ \>50% was considered significant heterogeneity). Funnel plots and Egger's regression model were used to assess for the likelihood of systematic bias. We included randomised controlled trials of calcium with or without vitamin D in the primary analyses. Randomised controlled trials in which supplemental vitamin D was provided to both treatment groups, so that the groups differed only in treatment by calcium, were included in calcium monotherapy subgroup analyses, while those comparing co-administered CaD with placebo or controls were included in the CaD subgroup analyses. We included all available data from trials with factorial designs or multiple arms. Thus, for factorial randomised controlled trials we included all study arms involving a comparison of calcium versus no calcium in the primary analyses and the calcium monotherapy subgroup analysis, but only arms comparing CaD with controls in the CaD subgroup analysis. For multi-arm randomised controlled trials, we pooled data from the separate treatment arms for the primary analyses, but each treatment arm was used only once. We undertook analyses of prespecified subgroups using a random effects model when there were 10 or more studies in the analysis and three or more studies in each subgroup and performed a test for interaction between subgroups. All tests were two tailed, and P\<0.05 was considered significant. All analyses were performed with Comprehensive Meta-Analysis (version 2, Biostat, Englewood, NJ).

Results
=======

Baseline characteristics
------------------------

We identified 59 randomised controlled trials of calcium intake that reported BMD as an outcome.[@ref7] [@ref12] [@ref13] [@ref14] [@ref15] [@ref16] [@ref17] [@ref18] [@ref19] [@ref20] [@ref21] [@ref22] [@ref23] [@ref24] [@ref25] [@ref26] [@ref27] [@ref28] [@ref29] [@ref30] [@ref31] [@ref32] [@ref33] [@ref34] [@ref35] [@ref36] [@ref37] [@ref38] [@ref39] [@ref40] [@ref41] [@ref42] [@ref43] [@ref44] [@ref45] [@ref46] [@ref47] [@ref48] [@ref49] [@ref50] [@ref51] [@ref52] [@ref53] [@ref54] [@ref55] [@ref56] [@ref57] [@ref58] [@ref59] [@ref60] [@ref61] [@ref62] [@ref63] [@ref64] [@ref65] [@ref66] [@ref67] [@ref68] [@ref69] [@ref70] Fifteen studied dietary sources of calcium (n=810 calcium, n=723 controls),[@ref16] [@ref17] [@ref18] [@ref19] [@ref20] [@ref21] [@ref22] [@ref23] [@ref24] [@ref25] [@ref26] [@ref27] [@ref28] [@ref29] [@ref30] and 51 studied calcium supplements (n=6547 calcium, n=5710 controls).[@ref7] [@ref12] [@ref13] [@ref14] [@ref15] [@ref17] [@ref19] [@ref20] [@ref21] [@ref22] [@ref26] [@ref28] [@ref31] [@ref32] [@ref33] [@ref34] [@ref35] [@ref36] [@ref37] [@ref38] [@ref39] [@ref40] [@ref41] [@ref42] [@ref43] [@ref44] [@ref45] [@ref46] [@ref47] [@ref48] [@ref49] [@ref50] [@ref51] [@ref52] [@ref53] [@ref54] [@ref55] [@ref56] [@ref57] [@ref58] [@ref59] [@ref60] [@ref61] [@ref62] [@ref63] [@ref64] [@ref65] [@ref66] [@ref67] [@ref68] [@ref69] [@ref70] Table 1[](#tbl1){ref-type="table"} shows study design and selected baseline characteristics for included studies of dietary calcium. Tables 2 and 3 show the study design and selected baseline characteristics for trials of calcium supplements, without and with additional vitamin D, respectively.[](#tbl2){ref-type="table"} [](#tbl3){ref-type="table"} Further details are in tables A-C in appendix 2. Of the 15 randomised controlled trials of dietary sources of calcium, 10 used milk or milk powder, two used dairy products, and three used hydroxyapatite preparations. Of the 51 trials of calcium supplements, 36 studied calcium monotherapy, 13 co-administered CaD, and two were multi-arm studies of both. Table 4 summarises other features of the trials[](#tbl4){ref-type="table"}. Most of them studied calcium without vitamin D in women aged \<70 living in the community; the mean baseline dietary calcium intake was \<800 mg/day; and most trials lasted ≤2 years. A calcium dose of \>500 mg/day was used in most trials, but a higher proportion of trials of calcium supplements used a dose of ≥1000 mg/day. Table C in appendix 2 shows our assessment of risk of bias. Of the 15 trials of dietary sources of calcium, we assessed two as low risk of bias, six as moderate risk, and seven as high risk. Of the 51 trials of calcium supplements, we assessed 19 as low risk of bias, 12 as moderate risk, and 20 as high risk.

###### 

 Design of randomised controlled trials and selected baseline characteristics of eligible trials of dietary calcium

  Trial                     Design                                                      Calcium dose (mg/d)   Vitamin D dose (IU/d)   Duration   Care setting   Total No of participants\*   No in Ca/controls group†   \% women   Mean age (years)
  ------------------------- ----------------------------------------------------------- --------------------- ----------------------- ---------- -------------- ---------------------------- -------------------------- ---------- ------------------
  Recker 1985^16^           2 arm: milk and control                                     NS                    ---                     2 y        Community      30                           16/14                      100        59
  Polley 1987^17^           4 arm: dairy, Ca, dairy/salt restrict, control              ≥1250                 ---                     9 mo       Community      269                          58/52                      100        57
  Nelson 1991^18^           2×2 factorial: ex/milk, ex/control, sed/milk, sed/control   831                   ---                     1 y        Community      41                           18/18                      100        60
  Chevalley 1994^19^        3 arm: OMC/D, CaD, P/D                                      800                   300 000 IM stat         18 mo      Community      93                           31/31                      85         72
  Prince 1995^20^           4 arm: milk, Ca, Ca/ex, P                                   1000                  ---                     2 y        Community      168                          42/42                      100        63
  Storm 1998^21^            3 arm: milk, Ca, P                                          NS                    ---                     2 y        Community      40                           20/20                      100        71
  Castelo-Branco 1999^22^   3 arm: OHC, Ca, control                                     3320                  ---                     2 y        Community      60                           17/16                      100        55
  Cleghorn 2001^23^         2 arm: milk, control                                        700                   ---                     1 y        Community      142                          56/59                      100        52
  Lau 2001^24^              2 arm: milk, control                                        800                   ---                     24 mo      Community      200                          95/90                      100        57
  Chee 2003^25^             2 arm: milk, control                                        1200                  ---                     24 mo      Community      200                          91/82                      100        59
  Albertazzi 2004^26^       3 arm: OHC, Ca, P                                           500                   ---                     6 mo       Community      153                          52/50                      100        68
  Daly 2006^27^             2 arm: milk, control                                        1000                  800                     2 y        Community      167                          85/82                      0          62
  Manios 2007^28^           3 arm: dairy, Ca, control                                   1200                  300                     12 mo      Community      112                          39/36                      100        61
  Kukuljan 2009^29^         2×2 factorial: milk, milk/ex, ex, control                   1000                  800                     12 mo      Community      180                          90/90                      0          61
  Gui 2012^30^              3 arm: milk, soy milk, control                              250                   ---                     18 mo      Community      141                          100/41                     100        56

Ca=calcium; restrict=restriction; ex=exercise; sed=sedentary; OMC=ossein-mineral complex; D=vitamin D; CaD=co-administered Ca and vitamin D; P=placebo; IM=intramuscular; OHC=ossein-hydroxyapatite complex.

\*Total number of randomised participants in all treatment arms.

†Number of participants in relevant arms from trial in whom bone mineral density was reported.

###### 

Design of randomised controlled trials and selected baseline characteristics of eligible trials of calcium supplements

  Trial                     Design                                           Calcium dose (mg/d)   Duration   Care setting   No of participants\*   No in Ca/controls group†   \% women   Mean age (y)
  ------------------------- ------------------------------------------------ --------------------- ---------- -------------- ---------------------- -------------------------- ---------- --------------
  Recker 1977^31^           3 arm: Ca, HRT, control                          1040                  2 y        Community      60                     22/20                      100        57
  Lamke 1978^32^            2 arm: Ca, P                                     1000                  12 mo      Community      40                     19/17                      100        60
  Hansson 1987^12^          4 arm: 30 mg NaF/Ca, 10 mg NaF/Ca, Ca, P         1000                  3 y        NS             50                     25/25                      100        66
  Polley 1987^17^           4 arm: Ca, dairy, dairy/salt restrict, control   1000                  9 mo       Community      269                    40/52                      100        57
  Riis 1987^34^             3 arm: Ca, HRT, P                                2000                  2 y        Community      43                     14/11                      100        51
  Smith 1989^35^            2 arm: Ca, P                                     1500                  4 y        Community      169                    70/77                      100        51
  Dawson-Hughes 1990^36^    3 arm: Ca, Ca, P                                 500                   2 y        Community      361                    158/93                     100        58
  Fujita 1990^37^           2 arm: Ca, control                               900                   2 y        Institution    32                     12/20                      100        80
  Elders 1991^39^           3 arm: Ca, Ca, P                                 1000 or 2000          2 y        Community      295                    198/97                     100        NS
  Prince 1991^40^           3 arm: Ca/ex, ex, HRT                            1000                  2 y        Community      80                     39/41                      100        57
  Lau 1992^42^              2×2 factorial: Ca, Ca/ex, ex/P, P                800                   10 mo      Institution    50                     27/23                      100        76
  Reid 1993^43^             2 arm: Ca *v* P                                  1000                  2 y        Community      135                    61/61                      100        58
  Strause 1994^45^          2×2 factorial: Ca, Ca/minerals, minerals, P      1000                  2 y        Community      113                    27/32                      100        66
  Prince 1995^20^           4 arm: Ca, Ca/ex, milk, P                        1000                  2 y        Community      168                    42/42                      100        63
  Fujita 1996^46^           3 arm: Ca, Ca, P                                 900                   2 y        Institution    58                     38/20                      100        81
  Perez-Jaraiz 1996^47^     4 arm: Ca, HRT, calcitonin, control              1000                  1 y        Community      52                     26/26                      100        50
  Recker 1996^48^           2 arm: Ca, P                                     1200                  4.3 y      Community      197                    91/100                     100        74
  Ricci 1998^51^            2 arm: Ca, P                                     1000                  6 mo       Community      43                     15/16                      100        58
  Riggs 1998^52^            2 arm: Ca, P                                     1600                  4 y        Community      236                    119/117                    100        66
  Storm 1998^21^            3 arm: Ca, milk, P                               1000                  2 y        Community      40                     20/20                      100        72
  Castelo-Branco 1999^22^   3 arm: Ca, OHC, control                          2500                  2 y        Community      60                     19/16                      100        54
  Ruml 1999^53^             2 arm: Ca, P                                     800                   2 y        Community      63                     25/31                      100        52
  Fujita 2000^54^           4 arm: Ca, Ca, Ca, P                             900                   4 mo       NS             38                     32/6                       100        55
  Peacock 2000^13^          3 arm: Ca, 25OHD, P                              750                   4 y        Community      438                    126/135                    72         74
  Son 2001^55^              3 arm: Ca, alphacalcidiol, P                     1000                  10 mo      Community      69                     22/21                      100        72
  Albertazzi 2004^26^       3 arm: Ca, OHC, P                                500                   6 mo       Community      153                    51/50                      100        68
  Prince 2006^61^           2 arm: Ca, P                                     1200                  5 y        Community      1460                   730/730                    100        75
  Reid 2006^62^             2 arm: Ca, P                                     1000                  5 y        Community      1471                   732/739                    100        74
  Manios 2007^28^           3 arm: Ca, dairy, control                        600                   12 mo      Community      112                    26/36                      100        62
  Reid 2008^65^             3 arm: Ca, Ca, P                                 600 or 1200           2 y        Community      323                    216/107                    0          56
  Chailurkit 2010^67,68^    2 arm: Ca, P                                     500                   2 y        Community      404                    178/165                    100        66
  Nakamura 2012^70^         3 arm: Ca, Ca, P                                 250 or 500            2 y        Community      450                    281/137                    100        60

Ca=calcium; HRT=hormone replacement therapy; P=placebo; ex=exercise; NaF=sodium fluoride; restrict=restriction; OMC=ossein-mineral complex; 25OHD=25-hydroxyvitamin D; NS=not stated.

\*Total number of randomised participants in all treatment arms.

†Number of participants in relevant arms from trial in whom bone mineral density was reported.

###### 

Design of randomised controlled trials and selected baseline characteristics of eligible trials of calcium supplements that also used vitamin D supplements

  Trial                    Design                                    Calcium dose (mg/d)   Vitamin D dose (IU/d)    Duration   Care setting   No of participants\*   No in Ca/control group†   \% women   Mean age (y)
  ------------------------ ----------------------------------------- --------------------- ------------------------ ---------- -------------- ---------------------- ------------------------- ---------- --------------
  Smith 1981^33^           2×2 factorial: CaD, ex, ex/CaD, P         750                   400                      3 y        Institution    80                     21/30                     100        82
  Orwoll 1990^38^          2 arm: CaD , P                            1000                  1000                     3 y        Community      86                     41/36                     0          58
  Chapuy 1992^41^          2 arm: CaD, P                             1200                  800                      18 mo      Institution    3270                   27/29                     100        84
  Aloia 1994^44^           3 arm: CaD, HRT/CaD, P/D                  600                   400                      2.9 y      Community      118                    34/36                     100        52
  Chevalley 1994^19^       3 arm: CaD, OMC/D, P/D                    800                   300 000 IM stat          18 mo      Community      93                     31/31                     89         72
  Dawson-Hughes 1997^49^   2 arm: CaD, P                             500                   700                      3 y        Community      445                    187/202                   55         71
  Baeksgaard 1998^50^      3 arm: CaD, CaD/multivitamins, P          1000                  560                      2 y        Community      160                    65/63                     100        62
  Chapuy 2002^56^          3 arm: CaD, CaD, P                        1200                  800                      2 y        Institution    610                    393/190                   100        85
  Grados 2003^57^          2 arm: CaD, P                             500                   400                      12 mo      Community      192                    95/97                     100        75
  Doetsch 2004^58^         2 arm: CaD, P                             1000                  800                      12 w       Community      30                     16/14                     NS         NS
  Harwood 2004^14^         4 arm: CaD, CaD, D, control               1000                  300 000 IM stat or 800   12 mo      Community      150                    75/75                     100        81
  Meier 2004^59^           2 arm: CaD, control                       500                   500                      6 mo       Community      55                     27/16                     67         56
  Riedt 2005^60^           3 arm: CaD/w-loss, D/w-loss, w-maintain   1200                  400                      6 mo       Community      55                     23/24                     100        61
  Jackson 2006^7^          2 arm: CaD, P                             1000                  400                      7 y        Community      2431                   1230/1201                 100        62
  Bolton-Smith 2007^63^    2×2 factorial: CaD, CaD/vit K, vit K, P   1000                  400                      2 y        Community      244                    99/110                    100        68
  Bonnick 2007^64^         3 arm: CaD/alend, CaD, alend/D            1000                  400                      2 y        Community      563                    282/281                   100        66
  Hitz 2007^15^            2 arm: CaD, P                             1200                  1400                     12 mo      Community      122                    34/45                     83         68
  Zhu 2008^66^             3 arm: Ca, CaD, P                         1200                  1000                     5 y        Community      120                    79/41                     100        75
  Karkkainen 2010^69^      2 arm: CaD, control                       1000                  800                      3 y        Community      593                    287/306                   100        67

Ca=calcium; HRT=hormone replacement therapy; P=placebo; CaD=co-administered calcium and vitamin D; ex=exercise; OMC=ossein-mineral complex; D=vitamin D; IM=intramuscular; w-loss=weight loss, w-maintain=weight maintenance; vit K=vitamin K; alend=alendronate; NS=not stated.

\*Total number of randomised participants in all treatment arms.

†Number of participants in relevant arms from trial in whom bone mineral density was reported.

###### 

Summary of selected characteristics of eligible trials of calcium intake. Data are number (percentage) of trials

  Characteristics of randomised controlled trials      Dietary sources of calcium (n=15)   Calcium supplements (n=51)
  ---------------------------------------------------- ----------------------------------- ----------------------------
  Agent studied:                                                                           
   Calcium monotherapy                                 11 (73)                             36 (71)
   Calcium with vitamin D                              4 (27)                              13 (25)
   Multi-arm study with calcium or calcium+vitamin D   0                                   2 (4)
  Calcium dose ≥1000 mg/d                              6 (40)                              34 (67)
  Calcium dose ≤500 mg/d                               2 (13)                              7 (14)
  Duration ≤2 years                                    15 (100)                            37 (73)
  Duration ≥3 years                                    0                                   13 (25)
  Participants living in community                     15 (100)                            45 (88)
  Most participants women                              13 (87)                             48 (94)
  Baseline mean age ≥70                                2 (13)                              18 (35)
  Baseline mean dietary calcium intake \<800 mg/d      9/13 (69)                           26/39 (67)

Primary analyses
----------------

Table 5[](#tbl5){ref-type="table"} summarises the results of the meta-analyses. Increasing calcium intake from dietary sources increased BMD by 0.6-1.0% at the total hip and total body at one year and by 0.7-1.8% at these sites and the lumbar spine and femoral neck at two years (figs 1 and 2[](#fig1){ref-type="fig"} [](#fig2){ref-type="fig"}. There was no effect on BMD at the forearm.

###### 

Pooled analyses of trials of dietary sources of calcium and calcium supplements

  Time point (years)   Trials of dietary sources of calcium          Calcium supplement trials   P (interaction)†                                               
  -------------------- -------------------------------------- ------ --------------------------- ------------------ -- ---- ------ ------------------ --------- ------
  **Lumbar spine**                                                                                                                                              
  1                    11                                     1260   0.6 (−0.1 to 1.3)           0.08                  27   3866   1.2 (0.8 to 1.7)   \<0.001   0.13
  2                    8                                      816    0.7 (0.3 to 1.2)            0.001                 21   6115   1.1 (0.7 to 1.6)   \<0.001   0.19
  \>2.5                0                                      ---    ---                         ---                   8    3861   1.0 (0.3 to 1.6)   0.003     ---
  **Femoral neck**                                                                                                                                              
  1                    8                                      1035   0.3 (−0.3 to 0.9)           0.30                  19   2651   1.2 (0.7 to 1.8)   \<0.001   0.02
  2                    7                                      783    1.8 (1.1 to 2.6)            \<0.001               14   2415   1.0 (0.5 to 1.4)   \<0.001   0.05
  \>2.5                0                                      ---    ---                         ---                   5    2257   1.5 (0.2 to 2.9)   0.025     ---
  Total hip                                                                                                                                                     
  1                    6                                      900    0.6 (0.3 to 1.0)            0.001                 7    1159   1.4 (0.6 to 2.3)   0.001     0.08
  2                    5                                      689    1.5 (0.7 to 2.4)            \<0.001               7    4366   1.3 (0.8 to 1.8)   \<0.001   0.63
  \>2.5                0                                      ---    ---                         ---                   6    3835   1.2 (0.5 to 1.9)   0.001     ---
  **Forearm**                                                                                                                                                   
  1                    4                                      418    0.0 (−0.4 to 0.5)           0.85                  10   791    1.0 (0.2 to 1.8)   0.014     0.04
  2                    2                                      171    0.1 (−0.3 to 0.4)           0.65                  10   857    1.5 (0.5 to 2.6)   0.005     0.01
  \>2.5                0                                                                                               5    437    1.8 (0.2 to 3.4)   0.025     
  **Total Body**                                                                                                                                                
  1                    3                                      433    1.0 (0.3 to 1.8)            0.009                 10   1255   0.7 (0.4 to 1.1)   \<0.001   0.47
  2                    2                                      358    0.9 (0.5 to 1.3)            \<0.001               6    3901   0.8 (0.5 to 1.1)   \<0.001   0.67
  \>2.5                0                                      ---    ---                         ---                   7    4164   0.8 (0.5 to 1.1)   \<0.001   ---

\*Weighted mean difference between groups in percentage change in bone mineral density (BMD) from baseline.

†Test for interaction between subgroup of trials of dietary sources of calcium and subgroup of calcium supplement trials.

![**Fig 1**Random effects meta-analysis of effect of dietary sources of calcium on percentage change in bone mineral density (BMD) from baseline at one year](taiv026209.f1_default){#fig1}

![**Fig 2**Random effects meta-analysis of effect of dietary sources of calcium on percentage change in bone mineral density (BMD) from baseline at two years](taiv026209.f2_default){#fig2}

When we restricted the analyses to the 12 randomised controlled trials of milk or dairy products, by excluding three trials of hydroxyapatite, there was little change in the results. Calcium supplements increased BMD at all five skeletal sites by 0.7-1.4% at one year (figs 3 and 4[](#fig3){ref-type="fig"} [](#fig4){ref-type="fig"}), by 0.8-1.5% at two years (figs 5 and 6[](#fig5){ref-type="fig"} [](#fig6){ref-type="fig"}), and by 0.8-1.8% at more than two and a half years (fig 7[](#fig7){ref-type="fig"}) (range of duration of trials was three to five years).

![**Fig 3**Random effects meta-analysis of effect of calcium supplements on percentage change in bone mineral density (BMD) for lumbar spine and femoral neck from baseline at one year](taiv026209.f3_default){#fig3}

![**Fig 4**Random effects meta-analysis of effect of calcium supplements on percentage change in bone mineral density (BMD) for total hip, forearm, and total body from baseline at one year](taiv026209.f4_default){#fig4}

![**Fig 5**Random effects meta-analysis of effect of calcium supplements on percentage change in bone mineral density (BMD) for lumbar spine and femoral neck from baseline at two years](taiv026209.f5_default){#fig5}

![**Fig 6**Random effects meta-analysis of effect of calcium supplements on percentage change in bone mineral density (BMD) for total hip, forearm, and total body from baseline at two years](taiv026209.f6_default){#fig6}

![**Fig 7**Random effects meta-analysis of effect of calcium supplements on percentage change in bone mineral density (BMD) from baseline in studies that lasted more than two and a half years](taiv026209.f7_default){#fig7}

When we used Egger's regression model and visual inspection of funnel plots, data seemed skewed toward positive results with increased calcium intake from dietary sources or supplements in about half of analyses that included five or more studies. The asymmetry of the funnel plot was caused by more small-moderate sized studies reporting larger effects of calcium on BMD than expected, raising the possibility of publication bias. Seven multi-arm randomised controlled trials included a dietary source of calcium arm and a calcium supplement arm,[@ref17] [@ref19] [@ref20] [@ref21] [@ref22] [@ref26] [@ref28] which allowed a direct comparison of the interventions. There were no significant differences between groups in BMD at any site in any individual trial, and there were also no significant differences between groups in BMD at any site or any time point in the pooled analyses (table D, appendix 2). We also tested for differences between the results of the trials of dietary sources of calcium and the trials of calcium supplements by comparing the two groups in subgroup analyses (table 4[](#tbl4){ref-type="table"}). There were no differences between the groups at any time point at the lumbar spine, total hip, or total body. At the femoral neck, there were greater increases in BMD at one year in the calcium supplement trials than in the dietary calcium trials, but at two years we found the opposite---that is, greater changes with dietary calcium than with calcium supplements. At the forearm, there were increases in BMD in the calcium supplement trials but no effect in the trials of dietary sources of calcium.

Subgroup analyses
-----------------

We carried out additional subgroup analyses when there were 10 or more trials in an analysis and three or more trials in each subgroup. In the trials of dietary sources of calcium, these criteria allowed analyses to be carried out only on the one year results for the lumbar spine. For the calcium supplement trials, we carried out analyses on the one year and two year results for the lumbar spine, femoral neck, and forearm results, and the one year result for total body. Table E in appendix 2 shows that there were no consistent differences between subgroups based on calcium monotherapy versus CaD, age, risk of bias, calcium dose of ≥1000 mg/day versus \<1000 mg/day, calcium dose of ≤500 mg/day versus \>500 mg/day, vitamin D dose, baseline dietary calcium intake, or baseline 25-hydroxyvitamin D level. We did not find enough trials to carry out subgroup analyses based on sex and residence (community versus institution).

Discussion
==========

Principal findings
------------------

Increasing calcium intake from dietary sources slightly increased bone mineral density (BMD) (by 0.6-1.8%) over one to two years at all sites, except the forearm where there was no effect. Calcium supplements increased BMD to a similar degree at all sites and all time points (by 0.7-1.8%). In the randomised controlled trials of calcium supplements, the increases in BMD were present by one year, but there were no further subsequent increases. Thus the increases from baseline at both two and over two and half years at each site were similar to the increases at one year. The increases in BMD with dietary sources of calcium were similar to the increases with calcium supplements, except at the forearm, in both direct comparisons of the two interventions in multi-arm studies and in indirect comparisons of the two interventions through subgroup analyses. The increases in BMD were similar in trials of calcium monotherapy and CaD, consistent with a recent meta-analysis reporting that vitamin D monotherapy had no effect on BMD.[@ref71] There were no differences in changes in BMD in our subgroup analyses between trials with calcium doses of ≥1000 mg/day and \<1000 mg/day or doses of ≤500 mg/day and \>500 mg/day, and in populations with baseline dietary calcium intake of \<800 mg/day and ≥800 mg/day. Overall, the results suggest that increasing calcium intake, whether from dietary sources or by taking calcium supplements, provides a small non-progressive increase in BMD, without any ongoing reduction in rates of BMD loss beyond one year. The similar effect of increased dietary intake and supplements suggests that the non-calcium components of the dietary sources of calcium do not directly affect BMD.

Strengths and limitations of the study
--------------------------------------

The strength of this meta-analysis is its comprehensive nature. We included 59 randomised controlled trials and assessed the effects of both dietary calcium sources and calcium supplements on BMD at five skeletal sites and at three time points. The size of the review permitted a comparison of the effects on BMD of different sources of calcium---dietary sources or supplements---and also the effects in important subgroups such as those defined by dose of calcium, use of co-administered vitamin D, and baseline clinical characteristics. The results are consistent with those from an earlier meta-analysis of 15 randomised controlled trials of calcium supplements, which reported an increase in BMD of 1.6-2.0% over two to four years.[@ref72]

An important limitation is that BMD is only a surrogate for the clinical outcome of fracture. We undertook the review, however, because many of the subgroup analyses in the dataset of trials with fracture as an endpoint have limited power,[@ref10] and a comparison between randomised controlled trials of dietary sources of calcium and calcium supplements with fracture as the endpoint is not possible because only two small randomised controlled trials of dietary sources of calcium reported fracture data.[@ref10] Another limitation is that in 60% of the meta-analyses, statistical heterogeneity between the studies was high (I^2^\>50%). This indicates substantial variability in the results of included trials, although this was often because of the presence of a small number of outlying results. Subgroup analyses generally did not substantially reduce or explain the heterogeneity. We used random effects meta-analyses that take heterogeneity into account, and their results should be interpreted as reflecting the average result across the group of trials.

Implications of findings
------------------------

The absence of any interaction with baseline dietary calcium intake or a dose-response relation suggests that increasing intake through dietary sources or through supplements does not correct a dietary deficiency (in which case greater effects would be seen in those with the lowest intakes or the highest doses). An alternative possibility is that increasing calcium intake has a weak anti-resorptive effect. Calcium supplements reduce markers of bone formation and resorption by about 20%,[@ref62] [@ref65] [@ref73] and increasing milk intake also reduces bone turnover by a similar amount.[@ref74] Suppression of bone turnover by this amount might lead to the small observed increases in BMD.

Increases in BMD of about 1-2% over one to five years are unlikely to translate into clinically meaningful reductions in fractures. The average rate of BMD loss in older post-menopausal women is about 1% a year. So the effect of increasing calcium intake is to prevent about one to two years of normal BMD loss, and if calcium intake is increased for more than one year it will slow down but not stop BMD loss. Epidemiological studies suggest that a decrease in BMD of one standard deviation is associated with an increase in the relative risk of fracture of about 1.5-2.0.[@ref75] A one standard deviation change in BMD is about equivalent to a 10% change in BMD. Based on these calculations, a 10% increase in BMD would be associated with a 33-50% reduction in risk of fracture. Therefore, the 1-2% increase in BMD observed with increased calcium intake would be predicted to produce a 5-10% reduction in risk of fracture. These estimates are consistent with findings from randomised controlled trials of other agents. The modest increases in BMD with increased calcium intake are smaller than observed with weak anti-resorptive agents such as etidronate[@ref76] and raloxifene.[@ref77] Etidronate, however, does not reduce vertebral or non-vertebral fractures, and raloxifene reduces vertebral but not non-vertebral fractures.[@ref78] In contrast, potent anti-resorptive agents such as alendronate, zoledronate, and denosumab increase BMD by 6-9% at the spine and 5-6% at the hip over three years.[@ref79] [@ref80] [@ref81] [@ref82] These changes are associated with reductions of 44-70% in vertebral fracture, 35-41% in hip fracture, and 15-25% in non-vertebral fractures.[@ref78] The magnitude of fracture reduction predicted by the small increases in BMD we observed with increased calcium intake are also consistent with the findings of our systematic review of calcium supplements and fracture.[@ref10] We observed small (\<15%) inconsistent reductions in total and vertebral fracture overall but no reductions in fractures in the large randomised controlled trials at lowest risk of bias and no reductions in forearm or hip fractures.

The large number of randomised controlled trials that studied increased calcium intake and BMD and the consistency of the results across different populations in studies using higher or lower doses of calcium and in studies of dietary calcium sources or calcium supplements does not reveal any obvious gaps in the evidence. Any future trials conducted should have a strong rationale as to why the results are likely to differ from the large body of existing trial evidence. It is usually recommended that anti-resorptive agents are co-prescribed with calcium and vitamin D, although randomised controlled trials of such agents have shown reductions in risk of fracture[@ref83] [@ref84] [@ref85] and the expected increases in BMD[@ref64] [@ref86] [@ref87] [@ref88] without the co-administration of calcium and vitamin D. Randomised controlled trials clarifying the role of calcium and vitamin D in individuals using anti-resorptive agents might be valuable. In subgroup analyses, we stratified trials by thresholds of baseline dietary calcium intake (800 mg/day) and 25-hydroxyvitamin D (50 nmol/L). The clinical consequences of low calcium intake or vitamin D status such as osteomalacia, however, probably occur only at much lower thresholds, and there might also be interactions between calcium intake and vitamin D status. Analyses of individual patient data would be valuable in exploring these issues further.

Conclusions
-----------

In summary, increasing calcium intake from dietary sources increases BMD by a similar amount to increases in BMD from calcium supplements. In each case, the increases are small (1-2%) and non-progressive, with little further effect on BMD after a year. Subgroup analyses do not suggest greater benefits of increasing calcium intake on BMD in any subpopulation based on clinically relevant baseline characteristics. The small effects on BMD are unlikely to translate into clinically meaningful reductions in fractures. Therefore, for most individuals concerned about their bone density, increasing calcium intake is unlikely to be beneficial.

### What is already known on this topic

1.  Older people are recommended to take at least 1000-1200 mg/day of calcium to treat and prevent osteoporosis

2.  Many people take calcium supplements to meet these recommendations

3.  Recent concerns about the safety of such supplements have led experts to recommend increasing calcium intake through food rather than by taking supplements, but the effect of increasing dietary calcium intake on bone health is not known

### What this study adds

1.  Increasing calcium intake either by dietary sources or supplements has small non-progressive effects on bone density

2.  These effects are unlikely to translate into clinically meaningful reductions in fractures
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